-
2 days ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).
-
2 days ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety. The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).
-
1 week ago | 
urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt
Author(s):,Panelists discuss evolving strategies for managing non–muscle-invasive bladder cancer (NMIBC), highlighting how risk stratification, resource limitations, and emerging therapies like gemcitabine-docetaxel are shaping treatment decisions, while emphasizing the urgent need for predictive tools and biomarkers to guide personalized care. The current standard of care for non–muscle-invasive bladder cancer (NMIBC) is highly dependent on risk stratification.
-
1 week ago | 
urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt
Author(s):,Panelists discuss how the ongoing BCG shortage has forced clinicians to adapt treatment strategies for non–muscle-invasive bladder cancer (NMIBC), balancing resource constraints with patient outcomes through dose adjustments, chemotherapy substitution, and earlier cystectomy, while emphasizing the importance of maintaining trial eligibility and adhering as closely as possible to evidence-based protocols.
-
1 week ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how real-world data from a recent Mayo Clinic study confirms the promising efficacy and favorable safety profile of nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting high cystectomy-free and overall survival rates, with longer follow-up needed to assess response durability.
-
1 week ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how recently FDA-approved therapies, including nadofaragene firadenovec, gemcitabine, and docetaxel, offer alternative treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), each with distinct mechanisms and administration methods. Physician Summary:Three recently FDA-approved agents for the treatment of high-risk, BCG-unresponsive NMIBC provide alternative options for patients who do not respond to standard BCG therapy.
-
3 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual risk and tolerance. Physician Summary:For patients with initially responsive NMIBC, maintenance therapy is a cornerstone of ongoing disease control, particularly in those with intermediate- or high-risk features.
-
3 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how timely identification of BCG-unresponsive NMIBC through defined response criteria enables dynamic risk stratification and guides critical decisions about escalating care to alternative treatments. Physician Summary:The typical time frame for observing a response to BCG therapy in NMIBC patients is within 3 to 6 months following initiation.
